In November 2015, the Bipartisan Budget Act of 2015 was signed into law, bringing with it a host of changes for the scope and structure of a variety of governmental programs. One such affected entity is the Medicaid Drug Rebate Program. This amendment is particularly noteworthy for pharmaceutical manufacturers, not so much for its contents, but for the events influencing its speedy ratification.
Alliance Life Sciences » Money Talks: Social Media and Inflation Penalties for Generic Drugs
Relevant Pages and Links